Article · 5 Oct 2026
Research articlePublished 18 May 2022
Assessment of Bioequivalence between the Higher Strengths of Pirfenidone 400 mg and 600 mg with Equivalent Doses of Pirfenidone 200 mg
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: The standard of care for idiopathic pulmonary fibrosis is pirfenidone 200 mg tablets thrice daily (t.i.d, 600 mg/day) which is titrated to achieve the desired maintenance dose i.e 1800-2400 mg/day (600 mg-800 mg, t.i.d). However, this is associated with a high pill burden and can impact patient compliance. Therefore, two higher strengths (400 mg and 600 mg) of pirfenidone tablets have been developed which offer greater flexibility to facilitate tailored dosing and likely to improve patient compliance. Methods: Two studies were conducted using an open-label, randomized, single-dose, two-treatment, two-period, twosequence, two-way crossover design in fed conditions with a washout period of 5-6 days between administration. In the first study, a single dose of 400 mg pirfenidone tablet was compared with 2 × 200 mg pirfenidone tablets and in the second study a single dose of 600 mg pirfenidone tablet was compared with 3 × 200 pirfenidone tablets. The assessment of bioequivalence between treatments in study 1: pirfenidone 1 × 400 mg vs. 2 × 200 mg tablets and study 2: pirfenidone 1 × 600 mg vs. 3 × 200 mg tablets was done by comparing the pharmacokinetic parameters: Cmax, AUC0-t and AUC0-∞. Results: 17 subjects were evaluated in the study with the lower strength (400 mg) and 43 subjects were evaluated in the study with the higher strength (600 mg). The ratios and 90% CI for the geometric mean in study 1 were 102.90% (89.33%-115.97%) for Cmax, 104.61% (92.74%-116.58%) for AUC0-t and 107.94% (95.75%-120.75%) for AUC0-∞. The ratios and 90% CI for the geometric mean in study 2 were 97.96% (91.41%-104.99%) for Cmax, 97.79% (93.96%-101.78%) for AUC0-t and 97.88% (94.10%-101.81%) for AUC0-∞. One adverse event was reported in study 1 and 4 adverse events in study 2. None of the adverse events were deemed to be serious AEs. All the treatments were well tolerated. Conclusion: Single doses of pirfenidone 400 mg tablets when compared with pirfenidone 2 × 200 mg tablets and pirfenidone 600 mg tablets when compared with the 3 × 200 mg tablets met the bioequivalence criteria in terms of rate and extent of absorption under fed condition.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Hemant Joshi”
- BylineArticles whose byline prints “Mukesh Kumar”
- BylineArticles whose byline prints “Jaideep Gogtay”
- BylineArticles whose byline prints “Meena Lopez”
- BylineArticles whose byline prints “Milind Gole”
- BylineArticles whose byline prints “Richa Sharma”